Dronabinol

also known as THC · tetrahydrocannabinol · delta-9-THC · Marinol · delta-9-tetrahydrocannabinol · Δ9-THC · BX-1 · High THC cannabis · +11 more

Other / unclassified

Developed for: cannabis dependence · post-traumatic stress disorder · chronic pain syndrome · obstructive sleep apnea syndrome · HIV infectious disease · osteoarthritis, knee · chemotherapy-induced toxicity · fibromyalgia
+47 more
· schizophrenia · Tourette syndrome · Alzheimer disease · attention deficit-hyperactivity disorder · chronic pancreatitis · dementia · irritable bowel syndrome · neuropathy, painful · opiate dependence · sickle cell disease · amyotrophic lateral sclerosis · anxiety · autism · breast carcinoma · cervical dystonia · chemotherapy-induced neuropathy · chondromalacia · chronic obstructive pulmonary disease · colon carcinoma · dysmenorrhea · endometriosis · esophageal disorder · essential tremor · HIV wasting syndrome · hypoproteinemia, hypercatabolic · intermediate coronary syndrome · malignant pancreatic neoplasm · migraine disorder · migraine with aura · migraine without aura · mood disorder · multiple sclerosis · nervous system injury · nutritional deficiency disease · obsessive-compulsive disorder · radiculopathy · spondylosis, cervical · synovitis · trichotillomania · anorexia nervosa · disruptive behavior disorder · eating disorder · hypertensive disorder · neurotic excoriation · olfactory nerve disorder · oral sensibility, disturbance of · vascular dementia
Investigated by: National Institute on Drug Abuse (NIDA) · Yale University · Johns Hopkins University · Solvay Pharmaceuticals · New York State Psychiatric Institute · Hadassah Medical Organization
+135 more
· Neurothera Labs Inc. · Radboud University Medical Center · VA Office of Research and Development · Wayne State University · Bionorica SE · Brain & Behavior Research Foundation · Center for Medicinal Cannabis Research · Central Institute of Mental Health, Mannheim · Charite University, Berlin, Germany · Columbia University · Dartmouth-Hitchcock Medical Center · European Union · INSYS Therapeutics Inc · King's College London · Massachusetts General Hospital · Mayo Clinic · Mclean Hospital · Medical University of South Carolina · Medical University of Vienna · Montefiore Medical Center · Multidisciplinary Association for Psychedelic Studies · National Cancer Institute (NCI) · National Center for Research Resources (NCRR) · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute on Aging (NIA) · Northwestern University · Oregon Health and Science University · Scilex Pharmaceuticals, Inc. · Substance Abuse and Mental Health Services Administration (SAMHSA) · Tilray · University of California, San Diego · University of Chicago · University of Colorado, Denver · University of Illinois at Chicago · University of Vermont · 3F Clinical Trials LTDA · ALS Association · Alzheimer's Clinical Trials Consortium · Alzheimer's Therapeutic Research Institute · Apnimed · Associação Brasileira de Cannabis Medicinal · Axim Biotechnologies · BASi Clinical Research Unit · Baylor College of Medicine · Bazelet Nehushtan LtD. · Benuvia Therapeutics Inc. · Bionorica Research GmbH · Biopharmaceutical Research Company · Bloom Labs Cannabis Solutions · Brigham and Women's Hospital · Bristol-Myers Squibb · CIHR Canadian HIV Trials Network · Cantonal Hospital of St. Gallen · Centre de Recherche du Centre Hospitalier de l'Université de Montréal · Changemark Research + Evaluation Ltd. · Christopher D. Verrico · City of Hope Medical Center · Colorado Joint Replacement · Colorado State University · CommonSpirit Health · Connecticut Pharmaceutical Solutions · Consortium for Medical Marijuana Clinical Outcomes Research · Daisy Pharma Opioid Venture, LLC · Duke University · Dystonia Medical Research Foundation · FG Brasil LTDA · FGK Clinical Research GmbH · Food and Drug Administration (FDA) · Hamilton Health Sciences Corporation · Harvard Medical School (HMS and HSDM) · Hebrew University of Jerusalem · Hektoen Institute for Medical Research · Hospital for Special Surgery, New York · all 141 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	MARINOL	—	1992-12-22	fda.gov ↗
Approved	US (FDA)	MARINOL	—	1985-05-31	fda.gov ↗

Trials 136 · started per year

today

US approved 1985

198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 09 trials
Phase 0	NCT04099355	Sep 2025 → Aug 2027	arthropathy	New York State Psychiatric Institute	Withdrawn	No outcome recorded
Phase 0	NCT06236815	Jan → Sep 2025	attention deficit-hyperactivity disorder, cognitive impairment with or without cerebellar ataxia	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 0	NCT04231643	Sep 2021 → Nov 2023	bipolar disorder	University of California, San Diego	Terminated	No outcome recorded
Phase 0	NCT03661892	Dec 2018 → Oct 2020	breast cancer, metastatic carcinoma in the bone	University of Arizona	Completed	No outcome recorded
Phase 0	NCT03560934	Sep 2018 → Sep 2021	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 0	NCT02335060	May → Sep 2014	—	Yale University	Terminated	No outcome recorded
Phase 0	NCT01591629	Nov 2011 → Jun 2012	—	Yale University	Completed	No outcome recorded
Phase 0	NCT01180374	Feb 2010 → Oct 2014	—	Yale University	Completed	No outcome recorded
Phase 0	NCT00842985	Sep 2008 → Oct 2009	cannabis dependence	Yale University	Completed	No outcome recorded
Phase 132 trials
Phase 1	NCT07176208	Dec 2025 → Apr 2026 overdue	cannabis dependence	Food and Drug Administration (FDA)	Recruiting	No outcome recorded
Phase 1	NCT05865470	Apr 2025 → Oct 2028 expected	poisoning, substance abuse	University of California, Los Angeles	Recruiting	No outcome recorded
Phase 1	NCT06609109	Mar 2025 → Apr 2029 expected	cannabis dependence, nicotine dependence	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06378957	Feb 2025 → Jul 2027 expected	—	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06772753	Feb 2025 → Jun 2027 expected	—	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06609083	Jan 2025 → Apr 2029 expected	—	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT06218550	Jul 2024 → Sep 2025	cannabis dependence	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT05742724	Jan → Feb 2024 overdue	chronic kidney disease	McMaster University	Active not recruiting	No outcome recorded
Phase 1	NCT06034314	Sep 2023 → Oct 2026 expected	HIV infectious disease	Yale University	Active not recruiting	No outcome recorded
Phase 1	NCT04226690	Nov 2022 → Dec 2023	—	Yale University	Completed	No outcome recorded
Phase 1	NCT05287256	May 2022 → Aug 2024	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT04920539	Feb 2022 → Dec 2025	HIV infectious disease	Yale University	Completed	No outcome recorded
Phase 1	NCT05002946	Jan → Apr 2022	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04958876	Oct → Dec 2021	—	Scilex Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04080427	Apr 2021 → May 2025	post-traumatic stress disorder	Wayne State University	Completed	No outcome recorded
Phase 1	NCT04199468	Sep 2019 → Jun 2022	—	Yale University	Completed	No outcome recorded
Phase 1	NCT03978156	Jul 2019 → Jan 2021	sickle cell disease	Yale University	Terminated	No outcome recorded
Phase 1	NCT03936907	Apr → Jul 2019	—	One World Cannabis Ltd.	Completed	No outcome recorded
Phase 1	NCT03098940	Jan → Apr 2018	thrombocytopenia 3	Axim Biotechnologies	Unknown	No outcome recorded
Phase 1	NCT03206463	Aug → Sep 2017	bipolar disorder	Yale University	Terminated	No outcome recorded
Phase 1	NCT02811939	Apr 2016 → Jun 2017	—	Yale University	Completed	No outcome recorded
Phase 1	NCT02710331	Mar 2016 → Dec 2026 expected	alcohol-induced mental disorder	Yale University	Active not recruiting	No outcome recorded
Phase 1	NCT02709954	Mar 2016 → Dec 2026 expected	alcohol-induced mental disorder, cannabis dependence	Yale University	Active not recruiting	No outcome recorded
Phase 1	NCT02404688	Dec 2015 → Dec 2026 expected	alcohol-induced mental disorder	Yale University	Active not recruiting	No outcome recorded
Phase 1	NCT02576912	Feb 2015 → Jun 2019	—	Yale University	Completed	No outcome recorded
Phase 1	NCT01964404	Jul 2014 → Sep 2021	cannabis dependence, schizophrenia	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 1	NCT02094599	Feb → May 2014	substance abuse	INSYS Therapeutics Inc	Completed	No outcome recorded
Phase 1	NCT00946348	Dec 2009 → Oct 2012	cannabis dependence, schizoaffective disorder, schizophrenia	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 1	NCT00438139	Mar 2007	cannabis dependence	National Institute on Drug Abuse (NIDA)	Terminated	No outcome recorded
Phase 1	NCT00314808	Apr 2006 → Oct 2011	glioma	Duke University	Completed	No outcome recorded
Phase 1	NCT01380457	Jan → Apr 2006	—	Par Pharmaceutical, Inc.	Completed	No outcome recorded
Phase 1	NCT00000737	—	HIV wasting syndrome, hypoproteinemia, hypercatabolic	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/28 trials
Phase 1/2	NCT07592390	May → Dec 2026 expected	attention deficit-hyperactivity disorder	University of Southern Santa Catarina	Recruiting	No outcome recorded
Phase 1/2	NCT06381180	Sep 2025 → Dec 2030 expected	cannabis dependence, post-traumatic stress disorder	Wayne State University	Not yet recruiting	No outcome recorded
Phase 1/2	NCT06477952	Aug 2025 → Dec 2026 expected	obstructive sleep apnea syndrome	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 1/2	NCT05272865	Aug 2023 → Feb 2024	chemotherapy-induced toxicity, neoplasm	LaSanta S A S	Unknown	No outcome recorded
Phase 1/2	NCT05101122	Oct 2021 → Apr 2022	obstructive sleep apnea syndrome	Apnimed	Completed	No outcome recorded
Phase 1/2	NCT03805750	Jan 2019 → Sep 2020	essential tremor	University of California, San Diego	Completed	No outcome recorded
Phase 1/2	NCT00893074	Apr 2009 → Oct 2011	cannabis dependence	Johns Hopkins University	Completed	No outcome recorded
Phase 1/2	NCT00079560	Dec 2001 → Aug 2004	HIV infectious disease	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 244 trials
Phase 2	NCT07635563	Jun 2026 → Apr 2027 expected	obstructive sleep apnea syndrome	Incannex Healthcare Ltd	Not yet recruiting	No outcome recorded
Phase 2	NCT05126888	Jun 2026 → Oct 2027 expected	Tourette syndrome	Neurothera Labs Inc.	Not yet recruiting	No outcome recorded
Phase 2	NCT07225777	Apr 2026 → Dec 2027 expected	cannabis dependence	Medical University of South Carolina	Recruiting	No outcome recorded
Phase 2	NCT06834997	Apr 2026 → Mar 2028	endometriosis	Baylor College of Medicine	Withdrawn	No outcome recorded
Phase 2	NCT07224698	Feb 2026 → Jun 2027 expected	post-traumatic stress disorder	Multidisciplinary Association for Psychedelic Studies	Not yet recruiting	No outcome recorded
Phase 2	NCT07199218	Oct 2025 → Dec 2027 expected	autism	Bazelet Nehushtan LtD.	Recruiting	No outcome recorded
Phase 2	NCT06731894	Oct 2025 → Jan 2028 expected	breast carcinoma, chemotherapy-induced neuropathy, colon carcinoma	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 2	NCT06647524	Jul 2025 → Dec 2027 expected	—	Yale University	Recruiting	No outcome recorded
Phase 2	NCT05519111	Apr 2025 → Apr 2027 expected	sickle cell disease	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 2	NCT06446479	Jul 2024 → Jun 2026 overdue	cannabis dependence	University of Colorado, Denver	Recruiting	No outcome recorded
Phase 2	NCT06454669	Jun 2024 → Dec 2028 expected	chronic pain syndrome	Christopher D. Verrico	Recruiting	No outcome recorded
Phase 2	NCT05477875	Feb 2024 → Jan 2025	hyperopia, myopia	University of Florida	Completed	No outcome recorded
Phase 2	NCT05644262	Dec 2023 → Apr 2026 overdue	dementia	University of Southern California	Active not recruiting	No outcome recorded
Phase 2	NCT05612711	Nov 2023 → Nov 2025	dementia	Ralph H. Johnson VA Medical Center	Withdrawn	No outcome recorded
Phase 2	NCT04992624	Feb 2022 → Oct 2026 expected	osteoarthritis, knee	Steven E Harte, PhD	Recruiting	No outcome recorded
Phase 2	NCT05239390	Dec 2021 → Jun 2023	Alzheimer disease	The Israeli Medical Center for Alzheimer's	Unknown	No outcome recorded
Phase 2	NCT03550352	Aug 2021 → May 2022	HIV infectious disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Terminated	No outcome recorded
Phase 2	NCT04596826	Nov 2020 → Oct 2024	retinal vascular disorder	Medical University of Vienna	Completed	No outcome recorded
Phase 2	NCT04448808	Oct 2020 → Jan 2025	post-traumatic stress disorder	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 2	NCT03928015	Oct 2019 → Jun 2021	—	CommonSpirit Health	Withdrawn	No outcome recorded
Phase 2	NCT04091789	Sep 2019 → Mar 2020	dysmenorrhea, migraine disorder, mood disorder	Pure Green	Unknown	No outcome recorded
Phase 2	NCT03635593	Jan 2019 → Jan 2021	chronic pain syndrome	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 2	NCT03766269	Dec 2018 → Jun 2019	chronic pain syndrome	Daisy Pharma Opioid Venture, LLC	Unknown	No outcome recorded
Phase 2	NCT03651726	Aug 2018 → Nov 2019	Tourette syndrome	Neurothera Labs Inc.	Unknown	No outcome recorded
Phase 2	NCT03646552	Jun 2018 → Apr 2019	obstructive sleep apnea syndrome	Neurothera Labs Inc.	Unknown	No outcome recorded
Phase 2	NCT03005119	Mar → Dec 2018	multiple sclerosis	PhytoTech Therapeutics, Ltd.	Unknown	No outcome recorded
Phase 2	NCT03098563	Nov 2017 → Nov 2023	osteoarthritis, knee	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02792257	Mar 2017 → May 2024	Alzheimer disease	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT03066193	Feb 2017 → Jun 2018	Tourette syndrome	Yale University	Completed	No outcome recorded
Phase 2	NCT02759185	Jan 2017 → Nov 2018	post-traumatic stress disorder	Multidisciplinary Association for Psychedelic Studies	Completed	No outcome recorded
Phase 2	NCT02901275	Dec 2016 → Mar 2020	—	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02608931	Nov 2015 → Mar 2019	Riley-Day syndrome	NYU Langone Health	Withdrawn	No outcome recorded
Phase 2	NCT01755091	Feb 2013 → Jun 2016	obstructive sleep apnea syndrome	University of Illinois at Chicago	Completed	No outcome recorded
Phase 2	NCT01562483	Oct 2012 → Jun 2014	chronic pain syndrome	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT01551511	Oct 2012 → Jun 2014	chronic pain syndrome, chronic pancreatitis	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT01318369	Oct 2011 → May 2013	chronic pancreatitis	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT01093976	Apr 2010 → Jan 2011	obsessive-compulsive disorder, trichotillomania	University of Chicago	Completed	No outcome recorded
Phase 2	NCT01253408	Sep 2009 → Dec 2011	irritable bowel syndrome	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT01786109	Sep 2009 → Dec 2011	irritable bowel syndrome	Michael Camilleri	Completed	No outcome recorded
Phase 2	NCT00743119	Jun 2008 → Oct 2009	—	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00418925	Sep 2006 → Nov 2009	cervical dystonia	University Health Network, Toronto	Unknown	No outcome recorded
Phase 2	NCT00123201	Sep 2005 → Mar 2007	migraine with aura, migraine without aura	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00373503	Aug 2005 → Jun 2007	cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00642499	Aug 2003 → Apr 2005	HIV infectious disease	Solvay Pharmaceuticals	Completed	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT07570953	Sep 2026 → Apr 2028 expected	obstructive sleep apnea syndrome	Mayo Clinic	Not yet recruiting	No outcome recorded
Phase 2/3	NCT07422311	May 2026 → May 2028 expected	—	Benuvia Therapeutics Inc.	Not yet recruiting	No outcome recorded
Phase 2/3	NCT05283161	Apr → Aug 2022	fibromyalgia	FG Brasil LTDA	Unknown	No outcome recorded
Phase 2/3	NCT02283281	May 2015 → Dec 2024	anxiety, neuropathy, painful	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 2/3	NCT01598896	May 2012 → Aug 2017	cannabis dependence	Mclean Hospital	Terminated	No outcome recorded
Phase 2/3	NCT01024335	Jan 2010 → Dec 2012	opiate dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT01020019	Jan 2010 → Sep 2014	cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2/3	NCT00153192	Apr 2001 → Apr 2006	chronic pain syndrome	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 310 trials
Phase 3	NCT07148206	Oct 2026 → May 2028 expected	opiate dependence	Montefiore Medical Center	Not yet recruiting	No outcome recorded
Phase 3	NCT05052541	Jan 2026 → Jun 2027 expected	spondylosis, cervical	University of Colorado, Denver	Recruiting	No outcome recorded
Phase 3	NCT06473701	Feb 2025 → Sep 2026 expected	chronic obstructive pulmonary disease	Vejle Hospital	Recruiting	No outcome recorded
Phase 3	NCT05335252	Jun 2022 → Dec 2026 expected	chondromalacia, osteoarthritis, knee, synovitis	Northwestern University	Active not recruiting	No outcome recorded
Phase 3	NCT04298528	Feb 2020 → Feb 2024	osteoarthritis, knee	Colorado Joint Replacement	Unknown	No outcome recorded
Phase 3	NCT03756974	Feb 2019 → Mar 2021	—	Bionorica SE	Completed	No outcome recorded
Phase 3	NCT04816994	Jan 2018 → Dec 2025 overdue	radiculopathy	Hadassah Medical Organization	Recruiting	No outcome recorded
Phase 3	NCT00553059	May 2008 → Aug 2014	cancer of unknown primary site, chemotherapy-induced toxicity	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00959218	Jun 2007 → Mar 2010	neuropathy, painful	Bionorica Research GmbH	Completed	No outcome recorded
Phase 3	NCT00642512	Jul 2003 → Jul 2004	chemotherapy-induced toxicity	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 410 trials
Phase 4	NCT05820685	Jul 2023 → Apr 2024	nervous system injury	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT04734080	Mar 2021 → Oct 2023	substance-related disorder	Hospital for Special Surgery, New York	Completed	No outcome recorded
Phase 4	NCT04155008	Mar → Apr 2021	cancer-related condition, head and neck cancer, lung cancer, malignant pancreatic neoplasm +1	Montefiore Medical Center	Terminated	No outcome recorded
Phase 4	NCT04374773	Oct 2020 → Feb 2026	cannabis dependence, pregnancy disorder	University of Washington	Completed	No outcome recorded
Phase 4	NCT04346407	Sep 2020 → Sep 2023	—	Jeffrey L Gum MD	Unknown	No outcome recorded
Phase 4	NCT03604341	Nov 2018 → May 2019	—	Oregon Health and Science University	Completed	No outcome recorded
Phase 4	NCT02569073	Jun 2017 → Aug 2019	esophageal disorder	Temple University	Withdrawn	No outcome recorded
Phase 4	NCT03008005	Jun 2017 → Dec 2019	post-traumatic stress disorder	Wayne State University	Completed	No outcome recorded
Phase 4	NCT01598207	Feb 2011 → May 2014	intermediate coronary syndrome	Yehudith Assouline-Dayan	Completed	No outcome recorded
Phase 4	NCT00965809	Oct 2009 → Oct 2012	post-traumatic stress disorder	Hadassah Medical Organization	Unknown	No outcome recorded
Phase not applicable15 trials
—	NCT07656350	Jun 2026 → Dec 2027 expected	—	King's College London	Recruiting	No outcome recorded
—	NCT06967051	May → Aug 2025 overdue	drug-induced mental disorder	Sobereye Inc.	Recruiting	No outcome recorded
—	NCT05644054	Jan 2023 → Apr 2024	fibromyalgia	Tel Aviv Medical Center	Unknown	No outcome recorded
—	NCT04871269	May 2021 → Dec 2023 overdue	—	Charite University, Berlin, Germany	Active not recruiting	No outcome recorded
—	NCT04605393	Jan 2021 → Jul 2023	cannabis dependence, schizophrenia	King's College London	Completed	No outcome recorded
—	NCT03655717	Nov 2018 → Jan 2021	alcohol-related disorders, poisoning	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT03907163	Jul → Nov 2018	—	Medical University of Vienna	Completed	No outcome recorded
—	NCT02604992	Nov → Dec 2015	—	INSYS Therapeutics Inc	Completed	No outcome recorded
—	NCT02310347	Dec 2014 → Sep 2016 overdue	—	Universitaire Ziekenhuizen KU Leuven	Active not recruiting	No outcome recorded
—	NCT02291562	Jul → Dec 2014	—	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
—	NCT02112292	Apr 2014 → Apr 2015	—	Wageningen University	Completed	No outcome recorded
—	NCT02291536	Feb → Dec 2014	—	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
—	NCT01149018	Jun 2010 → Jul 2012	fibromyalgia	Hadassah Medical Organization	Unknown	No outcome recorded
—	NCT00757822	Dec 2009 → Dec 2013	—	VA Office of Research and Development	Completed	No outcome recorded
—	NCT00812851	Apr 2005 → Apr 2008	amyotrophic lateral sclerosis	Cantonal Hospital of St. Gallen	Completed	No outcome recorded

Also used as a comparator or background therapy in 35 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 05 trials
Phase 0	NCT05906511 Comparator	Oct 2023 → Apr 2026 overdue	substance abuse	Yale University	Recruiting	No outcome recorded
Phase 0	NCT04294966 Comparator	Mar 2020 → May 2021	—	University of Chicago	Completed	No outcome recorded
Phase 0	NCT04025359 Comparator	May 2019 → Dec 2026 expected	—	Yale University	Recruiting	No outcome recorded
Phase 0	NCT03809546 Comparator	Nov 2018 → Jun 2021	—	University of Chicago	Completed	No outcome recorded
Phase 0	NCT03804840 Comparator	Mar 2017 → Dec 2018	—	University of Chicago	Completed	No outcome recorded
Phase 18 trials
Phase 1	NCT06948136 Comparator	Jun 2025 → Nov 2027 expected	cognitive disorder	Yale University	Recruiting	No outcome recorded
Phase 1	NCT06058702 Comparator	Sep 2024 → Dec 2028 expected	cannabis dependence, schizophrenia	Yale University	Recruiting	No outcome recorded
Phase 1	NCT02811510 Comparator	Jun 2016 → Jun 2026 overdue	—	Yale University	Recruiting	No outcome recorded
Phase 1	NCT02781519 Comparator	Jun 2015 → Jun 2026 overdue	—	Yale University	Recruiting	No outcome recorded
Phase 1	NCT01448772 Comparator	Oct → Dec 2011	—	INSYS Therapeutics Inc	Completed	No outcome recorded
Phase 1	NCT01323569 Comparator	Feb → Jun 2008	—	Jazz Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00624715 Comparator	Aug 2007 → Jun 2010	alcohol dependence	Yale University	Completed	No outcome recorded
Phase 1	NCT00490269 Comparator	Oct 2006 → Dec 2007	cannabis dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT07696871 Background	Jun → Dec 2026 expected	major depressive disorder	University of Southern Santa Catarina	Recruiting	No outcome recorded
Phase 1/2	NCT01394185 Comparator	Feb 2011 → Sep 2012	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1/2	NCT01832766 Comparator	Jun 2005 → May 2010	schizophrenia	University of Colorado, Denver	Terminated	No outcome recorded
Phase 1/2	NCT00682929 Comparator	Apr 2004 → Aug 2011	multiple sclerosis	University of California, Davis	Terminated	No outcome recorded
Phase 27 trials
Phase 2	NCT05269628 Comparator	Mar 2022 → Aug 2027 expected	multiple sclerosis	Tiffany J. Braley, MD, MS	Recruiting	No outcome recorded
Phase 2	NCT02460692 Comparator	Dec 2016 → Mar 2020	neuropathy, painful	University of California, San Diego	Completed	No outcome recorded
Phase 2	NCT01608217 Comparator	Jun 2012 → Jun 2014	Alzheimer disease, disruptive behavior disorder, vascular dementia	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT01302340 Comparator	Sep 2011 → Dec 2013	dementia	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00480441 Comparator	Aug 2006 → Jun 2009	cannabis dependence	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT00316563 Comparator	Aug 2006 → Nov 2009	cancer, eating disorder, olfactory nerve disorder, oral sensibility, disturbance of	Alberta Health services	Completed	No outcome recorded
Phase 2	NCT00217971 Comparator	Mar 2005 → Dec 2009	cannabis dependence	New York State Psychiatric Institute	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT07231965 Comparator	Jul 2026 → Dec 2027 expected	hypertensive disorder	Mayo Clinic	Not yet recruiting	No outcome recorded
Phase 2/3	NCT06146101 Comparator	May 2024 → Dec 2026 expected	obstructive sleep apnea syndrome	Incannex Healthcare Ltd	Active not recruiting	No outcome recorded
Phase 2/3	NCT04989413 Comparator	Oct 2022 → Feb 2025	migraine disorder	Hospital Israelita Albert Einstein	Terminated	No outcome recorded
Phase 2/3	NCT03530800 Comparator	Oct 2018 → Jul 2021	neurotic excoriation, trichotillomania	University of Chicago	Completed	No outcome recorded
Phase 33 trials
Phase 3	NCT03825965 Background	May 2023 → Feb 2025	osteoarthritis, knee	McMaster University	Completed	No outcome recorded
Phase 3	NCT03984214 Comparator	Dec 2019 → Sep 2024	chemotherapy-induced toxicity, malignant pancreatic neoplasm	Study Group of Medical Tumour Therapy (AGMT)	Completed	No outcome recorded
Phase 3	NCT00760695 Comparator	Oct 2008 → Dec 2011	anorexia nervosa	Odense University Hospital	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT02472847 Comparator	May 2012 → Jul 2014	—	University of Illinois at Chicago	Completed	No outcome recorded
Phase not applicable3 trials
—	NCT05226351 Comparator	Mar 2022 → Aug 2024	post-traumatic stress disorder	Charite University, Berlin, Germany	Completed	No outcome recorded
—	NCT02069366 Comparator	Nov 2014 → Dec 2019	post-traumatic stress disorder	Wayne State University	Completed	No outcome recorded
—	NCT00270803 Comparator	Jul 2004 → Dec 2005	cannabis dependence	Tel-Aviv Sourasky Medical Center	Completed	No outcome recorded

Evidence & citations 24 cited values

Every value below carries the sentence it was read from. 179 sources stand behind the page.

Field	Value	Cited text
Known as	dronabinol	“This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗ 109 “The potential sedative effect of dronabinol and the high expression of cannabinoid receptors on the hypoglossal motor nuclei makes this agent a good candidate for obstructive...” PMID 36805833 ↗ Jul 2023 “SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg.” NCT05126888 ↗ “Participants (N = 21; 57% women; mean age = 63.4 ± 6.4 yr) with knee osteoarthritis received oral combinations of placebo, hydromorphone (2 mg), and dronabinol (10 mg).” PMID 41481837 ↗ Dec 2025 “Dronabinol (synthetic Δ(9)- tetrahydrocannabinol) is used in patients with nausea and vomiting from chemotherapy and in AIDS patients for appetite stimulation.” PMID 26283236 ↗ Aug 2015 “The primary objective of the study is to examine the efficacy of oral dronabinol (BX-1) versus placebo in reducing nightmares in patients with PTSD.” PMID 37147642 ↗ May 2023 “BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.” NCT03756974 ↗ “dronabinol 20 and 40 mg (synthetic THC: Marinol, Solvay Pharmaceuticals, Brussels, Belgium) and matching placebos” PMID 21671456 ↗ Apr 2011 “Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA.” NCT05239390 ↗ “Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo” NCT00842985 ↗ “Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)” NCT04992624 ↗ “where they received a single 10 mg dose of oral THC (dronabinol).” PMID 38832949 ↗ Jun 2024 “Dronabinol oral solution, under fed conditions” NCT02604992 ↗ “THX-110 (a combination of Dronabinol and PEA)” NCT03646552 ↗ “A Bioavailability Study on Dronabinol” NCT03098940 ↗ “dronabinol” NCT05477875 ↗ NCT07148206 ↗ NCT01020019 ↗ NCT05335252 ↗ NCT00642512 ↗ NCT01786109 ↗ NCT01832766 ↗ NCT00490269 ↗ NCT00553059 ↗ NCT04294966 ↗ NCT05865470 ↗ NCT06454669 ↗ NCT06446479 ↗ NCT07225777 ↗ NCT02460692 ↗ NCT04099355 ↗ NCT00316563 ↗ NCT00743119 ↗ NCT05820685 ↗ NCT05226351 ↗ NCT01598896 ↗ NCT05906511 ↗ NCT03766269 ↗ NCT01253408 ↗ NCT06731894 ↗ NCT00946348 ↗ NCT00642499 ↗ NCT05519111 ↗ NCT02569073 ↗ NCT05612711 ↗ NCT03560934 ↗ NCT01093976 ↗ NCT01024335 ↗ NCT00893074 ↗ NCT00373503 ↗ NCT00314808 ↗ NCT03651726 ↗ NCT02710331 ↗ NCT06473701 ↗ NCT00418925 ↗ NCT01755091 ↗ NCT00079560 ↗ NCT07231965 ↗ NCT03928015 ↗ NCT03804840 ↗ NCT06146101 ↗ NCT04080427 ↗ NCT03655717 ↗ NCT07570953 ↗ NCT07422311 ↗ NCT03530800 ↗ NCT02608931 ↗ NCT00757822 ↗ NCT04734080 ↗ NCT04231643 ↗ NCT05272865 ↗ NCT00959218 ↗ NCT00153192 ↗ NCT00480441 ↗ NCT04025359 ↗ NCT03984214 ↗ NCT02811939 ↗ NCT04346407 ↗ NCT04871269 ↗ NCT00760695 ↗ NCT00217971 ↗ NCT02792257 ↗ NCT04155008 ↗ NCT03978156 ↗ NCT01964404 ↗ NCT00438139 ↗ NCT02811510 ↗ NCT01448772 ↗ NCT04596826 ↗ NCT06034314 ↗ NCT06834997 ↗ NCT00000737 ↗ NCT01394185 ↗ NCT04374773 ↗ NCT03066193 ↗ NCT02472847 ↗ NCT02094599 ↗ NCT07176208 ↗ NCT00812851 ↗ NCT02069366 ↗ NCT02310347 ↗ NCT03907163 ↗ NCT00123201 ↗ NCT03008005 ↗ NCT03604341 ↗ NCT06477952 ↗ NCT03809546 ↗ NCT01380457 ↗ NCT04298528 ↗ NCT07635563 ↗
Known as	AXIBAN	“Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)” NCT05644054 ↗
Known as	BX-1	“The primary objective of the study is to examine the efficacy of oral dronabinol (BX-1) versus placebo in reducing nightmares in patients with PTSD.” PMID 37147642 ↗ May 2023 1 “BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.” NCT03756974 ↗
Known as	D-9-Tetrahydrocannabinol	“Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function” NCT02291562 ↗
Known as	delta-9-tetrahydrocannabinol	“The aim of the current project is to investigate the impact of an activation of the cannabinoid system with an exogenous cannabinoid (dronabinol, i.e.,...” NCT05226351 ↗ 6 “Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.” PMID 35319274 ↗ Mar 2022 “Dronabinol is a synthetic oral formulation of delta-9-tetrahydrocannabinol (THC), a psychoactive constituent of the cannabis plant” NCT02792257 ↗ “Delta-9-tetrahydrocannabinol (THC) is the most abundant cannabinoid from the plant Cannabis sativa.” PMID 27720917 ↗ Oct 2016 “delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis” NCT01591629 ↗ “the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects” NCT04199468 ↗ “with an exogenous cannabinoid dronabinol (delta-9-tetrahydrocannabinol)” NCT04871269 ↗
Known as	delta-9-tetrahydrocannabinol (delta-THC)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01608217 ↗
Known as	delta-9-tetrahydrocannabinol [THC]	“dronabinol (synthetic delta-9-tetrahydrocannabinol [THC])” NCT07148206 ↗
Known as	delta-9-THC	“Active delta-9-THC administered intravenously over 20 minutes.” NCT06058702 ↗ 16 NCT01591629 ↗ NCT04605393 ↗ NCT02404688 ↗ NCT03206463 ↗ NCT01180374 ↗ NCT02709954 ↗ NCT06378957 ↗ NCT06218550 ↗ NCT04920539 ↗ NCT05287256 ↗ NCT02335060 ↗ NCT02576912 ↗ NCT04199468 ↗ NCT06058702 ↗ NCT06948136 ↗ NCT06236815 ↗
Known as	Delta-THC	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302340 ↗
Known as	High THC cannabis	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02759185 ↗ 1 NCT07224698 ↗
Known as	Marinol	“This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗ 12 “This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol...” NCT06834997 ↗ “THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler.” NCT03804840 ↗ “THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler.” NCT03809546 ↗ “Dronabinol (Marinol®) is FDA-approved for the treatment of anorexia/weight loss in AIDS and for nausea/emesis associated with chemotherapy” NCT02792257 ↗ “Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain” NCT00153192 ↗ “dronabinol 20 and 40 mg (synthetic THC: Marinol, Solvay Pharmaceuticals, Brussels, Belgium) and matching placebos” PMID 21671456 ↗ Apr 2011 “oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana)” NCT00682929 ↗ “Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)” NCT04992624 ↗ “dronabinol (also known as THC or by the trade name Marinol)” NCT00079560 ↗ “THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals)” NCT04294966 ↗ “5 mg Dronabinol (Marinol®) + Placebo Beverage” NCT07176208 ↗ “Marinol (Dronabinol)” NCT00316563 ↗
Known as	Namisol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01318369 ↗
Known as	SP-104	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05002946 ↗ 1 NCT04958876 ↗
Known as	SYNDROS	“Drug: Dronabinol (SYNDROS) Oral solution of SYNDROS (5 mg/mL)” NCT05272865 ↗ 1 NCT03661892 ↗
Known as	synthetic THC	“dronabinol (synthetic THC)” NCT04099355 ↗
Known as	synthetic Δ(9)- tetrahydrocannabinol	“Dronabinol (synthetic Δ(9)- tetrahydrocannabinol) is used in patients with nausea and vomiting from chemotherapy and in AIDS patients for appetite stimulation.” PMID 26283236 ↗ Aug 2015
Known as	synthetic Δ9-THC	“THX-110 (Dronabinol (synthetic Δ9-THC) and PEA)” NCT03646552 ↗
Known as	tetrahydrocannabinol	“This study will examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety,...” NCT00490269 ↗ 38 “Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard...” NCT03984214 ↗ “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗ “This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes -...” NCT03936907 ↗ “Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a...” NCT07696871 ↗ “Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg...” NCT03005119 ↗ “Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses.” NCT07199218 ↗ “The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes.” NCT06609109 ↗ “The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of cigarettes.” NCT06609083 ↗ “Cannabidiol (CBD) is the active ingredient of interest because of its anti-inflammatory effects and lack of psychoactive effects seen with tetrahydrocannabinol (THC).” NCT03825965 ↗ “Tetrahydrocannabinol (THC) has shown efficacy in alleviating chronic pain, particularly in disorders characterized by central sensitization.” PMID 41199355 ↗ Nov 2025 “The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil.” NCT05644262 ↗ “oral tablet formulation of natural Cannabidiol (CBD) at 40 mg and 100 mg alone and in combination with Tetrahydrocannabinol (THC)” NCT04226690 ↗ “cannabis oils containing tetrahydrocannabinol (THC) and cannabidiol (CBD) consumed orally in people living with HIV” PMID 30659041 ↗ Jan 2019 “The two active cannabinoids of interest in this trial are tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD).” NCT03635593 ↗ “Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo” NCT05052541 ↗ “This study attempts to characterize the effects of tetrahydrocannabinol (THC).” NCT00624715 ↗ “Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).” NCT03805750 ↗ “Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.” NCT04816994 ↗ “Tetrahydrocannabinol (THC) in cannabis (CNB)” NCT06647524 ↗ “2.5mg tetrahydrocannabinol oil” NCT07656350 ↗ NCT05283161 ↗ NCT02291536 ↗ NCT06967051 ↗ NCT02291562 ↗ NCT04989413 ↗ NCT05742724 ↗ NCT00270803 ↗ NCT05269628 ↗ NCT02112292 ↗ NCT01551511 ↗ NCT04992624 ↗ NCT06381180 ↗ NCT01149018 ↗ NCT01562483 ↗ NCT06772753 ↗ NCT00965809 ↗ NCT02283281 ↗
Known as	THC	“This study will examine the effects of oral dronabinol tetrahydrocannabinol (THC) on withdrawal symptoms in marijuana dependent volunteers, and evaluate the safety,...” NCT00490269 ↗ 44 “Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard...” NCT03984214 ↗ “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ “Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗ “This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes -...” NCT03936907 ↗ “Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a...” NCT07696871 ↗ “To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic...” NCT04989413 ↗ “Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg...” NCT03005119 ↗ “Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses.” NCT07199218 ↗ “The overall purpose of this study is to examine the effect of pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-tetrahydrocannabinol (THC).” NCT02576912 ↗ “Cannabidiol (CBD) is the active ingredient of interest because of its anti-inflammatory effects and lack of psychoactive effects seen with tetrahydrocannabinol (THC).” NCT03825965 ↗ “The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects.” NCT04816994 ↗ “The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects.” NCT02283281 ↗ “THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler.” NCT03809546 ↗ “The included studies tested natural delta-9-tetrahydrocannabinol (THC) (Namisol) and two types of synthetic THC analogue (dronabinol and nabilone).” PMID 34532852 ↗ Sep 2021 “Tetrahydrocannabinol (THC) has shown efficacy in alleviating chronic pain, particularly in disorders characterized by central sensitization.” PMID 41199355 ↗ Nov 2025 “The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil.” NCT05644262 ↗ “Dronabinol is a synthetic oral formulation of delta-9-tetrahydrocannabinol (THC), a psychoactive constituent of the cannabis plant” NCT02792257 ↗ “oral tablet formulation of natural Cannabidiol (CBD) at 40 mg and 100 mg alone and in combination with Tetrahydrocannabinol (THC)” NCT04226690 ↗ “CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)” NCT05283161 ↗ “Oral THC (dronabinol) is known to have a slower onset and longer duration of action compared with smoked marijuana.” NCT00743119 ↗ “Delta-9-tetrahydrocannabinol (THC) is the most abundant cannabinoid from the plant Cannabis sativa.” PMID 27720917 ↗ Oct 2016 “Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function” NCT02291562 ↗ “OBJECTIVE: Examine whether synthetic THC (dronabinol) augments PE effectiveness.” PMID 41270825 ↗ Nov 2025 “delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis” NCT01591629 ↗ “the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects” NCT04199468 ↗ “This study attempts to characterize the effects of tetrahydrocannabinol (THC).” NCT00624715 ↗ “Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).” NCT03805750 ↗ “10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule” NCT06967051 ↗ “dronabinol (also known as THC or by the trade name Marinol)” NCT00079560 ↗ “one dose of 5 mg THC (Dronabinol) with a placebo beverage” NCT07176208 ↗ “THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals)” NCT04294966 ↗ “Drug: Tetrahydrocannabinol (THC)” NCT06772753 ↗ “Tetra Hydro Cannabinol (THC)” NCT00270803 ↗ “Tetrahydrocannabinol (THC)” NCT04992624 ↗ “oral THC (20mg dronabinol)” NCT06446479 ↗ “Tetrahydrocannabinol (THC)” NCT05269628 ↗ NCT06647524 ↗ NCT00682929 ↗ NCT02781519 ↗ NCT06609083 ↗ NCT06609109 ↗ NCT03635593 ↗ NCT03550352 ↗ NCT05052541 ↗
Known as	Δ9-THC	“The development of Namisol®, a tablet containing purified Δ9-THC showing an improved pharmacokinetic profile, provides the opportunity to test the analgesic potential of Δ9-THC...” NCT01551511 ↗ 2 “The Safety, Tolerability, and Analgesic Efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain” NCT01318369 ↗ “Dronabinol is a licensed form of Δ9-THC.” PMID 32178232 ↗ Mar 2020
Action	Activate	“cannabinoid agonist hypothesized to decrease MJ withdrawal” NCT00373503 ↗
Modality	Other / unclassified	“utilizing Dronabinol, a cannabinoid known to decrease incidence of nausea and vomiting” NCT00314808 ↗
Route	Inhaled	“Oral THC 13mg and 17mg smoked in low nicotine cigarettes” NCT00270803 ↗
Route	Oral	“Oral THC 13mg and 17mg smoked in low nicotine cigarettes” NCT00270803 ↗